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ABSTRACT
Analysis of cell-free DNA using next-generation sequencing (NGS) is a powerful 
tool for the detection/monitoring of alterations present in circulating tumor DNA 
(ctDNA). Plasma extracted from 171 patients with a variety of cancers was analyzed 
for ctDNA (54 genes and copy number variants (CNVs) in three genes (EGFR, 
ERBB2 and MET)). The most represented cancers were lung (23%), breast (23%), 
and glioblastoma (19%). Ninety-nine patients (58%) had at least one detectable 
alteration. The most frequent alterations were TP53 (29.8%), followed by EGFR 
(17.5%), MET (10.5%), PIK3CA (7%), and NOTCH1 (5.8%). In contrast, of 222 
healthy volunteers, only one had an aberration (TP53). Ninety patients with non-
brain tumors had a discernible aberration (65% of 138 patients; in 70% of non-
brain tumor patients with an alteration, the anomaly was potentially actionable). 
Interestingly, nine of 33 patients (27%) with glioblastoma had an alteration (6/33 
(18%) potentially actionable). Overall, sixty-nine patients had potentially actionable 
alterations (40% of total; 69.7% of patients (69/99) with alterations); 68 patients 
(40% of total; 69% of patients with alterations), by a Food and Drug Administration 
(FDA) approved drug. In summary, 65% of diverse cancers (as well as 27% of 
glioblastomas) had detectable ctDNA aberration(s), with the majority theoretically 
actionable by an approved agent.
INTRODUCTION
The detection and investigation of molecular 
alterations has increased our knowledge of oncogenic 
mechanisms, and led to the use of targeted cancer therapies 
matched to patients’ specific molecular aberrations [1–7]. 
Specific examples include the use of EGFR tyrosine 
kinase inhibitors in non-small cell lung cancer (NSCLC) 
with an EGFR mutation [8], BRAF inhibitors in melanoma 
harboring BRAF mutations [9,10], or imatinib for chronic 
myelogenous leukemia [11,12]. Currently, most of the 
molecular tests are performed on archived tissues at a 
single time point, which is often a limiting factor. These 
invasive biopsies involve risks for patients, they are costly, 
time consuming, and may pose related complications of 
tissue acquisition. Samples used for testing are often from 
archived tissue that is several months old [1,2], which may 
not provide a recent picture of the molecular background 
of the tumor. In addition, patients with metastatic disease 
often have multiple involved sites, but usually have only 
one tumor biopsied and interrogated. While the testing 
might provide information about the genomic landscape 
of this particular site, it may not reflect the full genomic 
make-up of the cancer, as it has been shown that metastatic 
disease exhibits considerable heterogeneity [13–15]. 
Furthermore, it has been established that the portfolio of 
alterations found in tumors evolve with time. For instance, 
patients with non-small cell lung cancers treated with an 
EGFR inhibitor to target an EGFR mutation nearly always 
develop resistance, due to secondary mutations [16–18]. 
Therefore, molecular assays that detect these genomic 
changes without repeat invasive tissue biopsies are 
needed. One approach that could be useful is to investigate 
circulating tumor cell DNA (cell-free DNA) shed into the 
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circulation or released when cancer cells die [19]. This 
technology has emerged rapidly, with detection of the 
small amounts of tumor DNA present in the blood being 
virtually impossible even a few years ago. More recently, 
circulating cell-free tumor DNA has been successfully 
analyzed for single gene aberrations [20–22]. Cell-free 
DNA assays analyzing complete exons in multiple genes 
via next-generation sequencing (NGS) are now becoming 
feasible. Here we report the results of liquid biopsies in 
171 patients whose blood was analyzed for 54 genes via 
NGS in circulating tumor, cell-free DNA.
RESULTS
Analysis of control samples from healthy persons
During the technology development process, 79 
healthy normal controls (source: AllCells, http://www.
allcells.com) were tested and, in those, a single TP53 
R248Q mutation (heavy smoker, but no history of cancer) 
was seen, typical of a somatic mutation. During patient 
testing, samples from an additional 143 healthy persons 
were analyzed as controls (not blinded). These controls 
comprised about 60% male, with age ranging from 20-
50 years old. None of these individuals had a detectable 
somatic mutation in the 54 gene panel (single nucleotide 
polymorphisms (SNPs) were commonly seen but these are 
ascertained as germline SNPs because they occur at close to 
50% or 100% mutant allele frequencies in cell-free DNA).
Patient characteristics
Our population comprised 171 patients with diverse 
cancers who had a biopsy-free next-generation sequencing 
ctDNA test performed on their blood. Patient’s median age 
was 57 years old (range 19-87). There was a predominance 
of women over men (n=104 (61%): n=67 (39%)), and the 
most commonly represented cancers were lung (23%), 
breast (23%), and glioblastoma (19%) Table 1.
Circulating tumor DNA (ctDNA) sequencing 
results
The median time from sample receipt by the 
testing laboratory to results was 13 days (95%CI 12-
13 days; range 6-27 days). In our 171 tested patients, 
238 alterations were identified, with the majority being 
mutations (n=211, 89%). Eleven percent of the identified 
alterations were amplifications (27/238), although only 
3 genes were tested for copy numbers (ERBB2, EGFR, 
and MET). The most frequent alterations identified were 
TP53 (29.8%), followed by EGFR (17.5%), MET (10.5%), 
PIK3CA (7%), and NOTCH1 (5.8%) (Figure 1).
Of the total, 99 patients (58%) had at least one 
detectable alteration(s). This includes 65% (90/138) of 
patients with cancers other than glioblastoma, and 27% 
(9/33 of glioblastoma cases). Specifically, 26% of patients 
had one alteration, and 32% had at least two alterations. 
Patients had a median of one alteration (average 1.4, 
range 0-19), Figure 2A. Gastrointestinal, lung, breast, 
and genitourinary cancers harbored the most alterations, 
with 83%, 60%, 45%, and 40% of cases bearing at 
least two alterations, respectively. Interestingly, while 
the majority of patients with glioblastoma (73%) did 
not harbor a discernible alteration, 27% (N=9/33) had 
an alteration (Figure 2B), most commonly TP53 and 
NOTCH1 anomalies (detected in four and three patients, 
respectively).
When examining the tumor types comprising the 
most patients (lung and breast cancers, each n=40), we 
found that the most frequent alterations reported were 
TP53 (32.5%), HER1/2 (27.5%), and PIK3CA (25%) in 
breast cancer cases (Figure 3A). In lung cancer cases, 
TP53 alterations were detected in 50% of the cases, 
followed by EGFR (27.5%) and MET (17.5%) alterations 
(Figure 3B).
Actionability of the detected alterations
Of the total of 171 analyzed patients, 69 had 
potentially actionable alterations (40% of total, 70% of 
the patients with alterations detected). Indeed, all these 
69 patients had at least one matched experimental drug 
available in clinical trials. Among these 69 patients, 68 
patients (99% of 69 or 40% of total patients) also had 
a least one matched FDA- approved drug (n=9 patients 
with on-label use), Figure 4 and Table 2. Of note, the 
majority of patients with gastrointestinal, lung, and 
breast cancers had actionable alterations (83%, 60%, and 
52.5%, respectively)—in all the cases with an actionable 
aberration, the alteration could be matched to an FDA-
approved drug, Figure 4B.
On the other hand, 102 patients (60%) had no 
actionable alterations. In 72 of the 102 patients (70.6%) 
(or 42% of the total of 171 patients), there was no 
alteration detected. In addition, some patients (n=30, 
17.5% of the 171 patients) had alterations, but they were 
not theoretically actionable with currently available drugs, 
either approved or investigational (Figure 4).
DISCUSSION
Herein, we studied the molecular alterations 
identified in 171 patients with diverse cancers using 
targeted next-generation sequencing that analyzed 
circulating tumor DNA (ctDNA) extracted from plasma. 
We found that 58% of our patients demonstrated at least 
one molecular alteration, and 32% had two or more 
alterations. The most frequent alterations were TP53 
mutations, detected in nearly 30% of our patients, similar 
to previous reports wherein tissue was interrogated 
[23]. Of interest, the frequency of some alterations, 
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Table 1: Population characteristics
Parameters Total patients, N = 171
Gender
 Women 104 (61%)
 Men 67 (39%)
Age (median, range) 57.4 years (19-87)
Turn over timea (median, 95%CI) 13 days (12-13)
Tumor origin
 Lung 40 (23.4%)
 Breast 40 (23.4%)
 Glioblastoma 33 (19.3%)
 Genitourinary 10 (5.8%)
 Gastrointestinal 6 (3.5%)
 Unknown primary 39 (22.8%)
 Otherb 3 (1.8%)
Number of patients with ≥ 1 alteration 99 (58%)
aTime from blood reception to results
bOther included: melanoma, n=1; sarcoma, n=1; thymic sarcoma, n=1
Figure 1: List of altered genes. Overall, 211/238 (89%) alterations were mutations and 27/238 (11%) were amplifications. Of 29 
patients with EGFR alterations, 11 (38%) had an EGFR amplification only; two (7%), both an EGFR amplification and EGFR mutation(s); 
and 16 (55%) had EGFR mutation(s) only. Of eight patients with ERBB2 anomalies, two (25%) had an ERBB2 amplification only; two 
(25%), both an ERBB2 amplification and ERBB2 mutation(s); and four (50%), only an ERBB2 mutation. Of 18 patients with a MET 
aberration, 10 (56%) had a MET amplification only (10/18=56%) and eight (44%), a MET mutation only.
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such as MET in breast and lung tumors, was higher than 
previously reported, though the rates reported vary widely 
by study [24–27]. The higher rates of MET anomalies in 
our study could be due to the advanced state of the patients 
who usually undergo ctDNA testing, the relatively small 
number of patients with each disease type in our study, or 
the propensity for DNA bearing MET-related alterations to 
be shed into the blood.
Forty percent of patients had a potentially actionable 
alteration. Among the 99 patients with alterations 
detected, 70% had a potentially actionable alteration. 
Of note, three recent actionability studies performed on 
tumor samples [28–30] (not ctDNA) report that 83-90% 
percent of patients had at least one actionable alteration, 
which is higher than in earlier reports, perhaps because 
more comprehensive panels are now in use for tissues, 
and more targeted drugs have been approved and entered 
clinical trials. The ctDNA assay’s actionability was 
based on a panel of 54 genes (point mutations tested 
for all genes and copy numbers assessed in three of the 
54 genes) (other genomic alterations such as indels and 
fusions were not included at that time). In contrast, the 
Figure 2: Description of the number of alterations identified in 171 patients. Panel A. displays the number of patients per 
designated number of alterations (total=238 alterations; median 1 alteration per patient, range 0-19). A total of 99 patients (58%) had 
alterations(s). Panel B. describes the percentage of patients with the designated number of alterations, by histology. As an example, for 
patients with lung cancer: 20% had no alterations, 20% had 1 alteration, and 60% had ≥2 alterations reported. Other included: unknown 
primary, n=39; melanoma, n=1; sarcoma, n=1; thymic sarcoma, n=1.
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previous publications on tissue-based studies utilized 
larger panels of about 200 genes assessed by NGS [28–
30]. Furthermore, the patient populations examined, as 
well as the sensitivity of ctDNA versus tissue assays may 
be other factors that account for these differences. Indeed, 
in our study, 42% of patients did not have any detectable 
alteration. This was most prominent for glioblastoma, 
where 73% of patients (N = 33 total tested) had no 
discernible alteration in their ctDNA. Of interest in this 
regard, Bettegowda et al. [31] demonstrated the ability to 
detect any ctDNA (albeit without sequencing the genes 
in the ctDNA) in over 75% of 640 patients with various 
cancer types, but in less than 50% of primary brain, renal, 
prostate, or thyroid cancers, suggesting that physical 
Figure 3: Most frequent alterations detected in breast and lung cancers. Bar graphs representing frequencies of the most 
frequent alterations for breast cancer cases Panel A. and lung cancer cases Panel B. Alterations harbored by ≥ 2 patients have been 
included. Numbers into brackets indicate the number of patients with the designated alteration.
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Figure 4: Analysis of actionability in 171 patients with diverse cancers. Panel A. there is some overlapping as some patients 
might have approved agents on and off-label, as well as experimental drugs options for their disease - patients described in box A (on label 
use) all also have “off label use” options and are included in box B (Off-label use). Similarly, patients described in boxes A and B all also 
have clinical trial options and are included in box C. All patients with actionable alterations had at least one clinical trial suggested. Panel B. 
displays the percentages of actionability data by tumor sites. Other included: unknown primary, n=39; melanoma, n=1; sarcoma, n=1; 
thymic sarcoma, n=1.
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obstacles such as the blood-brain barrier and mucin could 
prevent ctDNA from entering the circulation [32]. For 
patients with primary brain cancers, cerebral spinal fluid 
may serve as an alternative “liquid biopsy” by enabling a 
more direct measurement of circulating DNA [33]. On the 
other hand, it is interesting that 27% of our patients with 
glioblastoma did have a discernible aberration on ctDNA 
testing, suggesting the possibility that, as this technology 
improves and incorporates highly prevalent alterations 
such as EGFR vIII indels, it may become usable for even 
higher percentages of these patients.
Overall, 65% of patients with malignancies other 
than brain tumors had at least one identifiable anomaly in 
their ctDNA. Sixty-eight patients (40%) had abnormalities 
that could be prosecuted by at least one drug that was 
approved for another disease (off-label use); and 9 patients 
(5%) had at least one approved agent in their disease (on-
label use). Overall, 70% of patients with alteration(s) had 
an aberration potentially actionable by an experimental 
agent in clinical trials or by an approved agent. Previous 
experience suggests that patient eligibility for these 
clinical trials or their conduct at a limited number of 
enrolling sites, as well as difficulty obtaining coverage for 
off-label drug use, might limit patients’ access to cognate 
medications [2].
Actionability by drugs that were FDA-approved was 
common in breast (52.5%) and lung cancers (60%). For 
lung cancers, EGFR alterations were frequent alterations; 
they are actionable with approved drugs (since several 
EGFR inhibitors are approved, including erlotinib, which 
is authorized for lung cancer). For breast cancers, most of 
the alterations actionable with an approved drug were in 
the PTEN/PI3K/mTOR axis (with several mTor inhibitors 
approved, including everolimus, which is on-label for 
breast cancer) or in the HER pathway.
There were several limitations to this study. First, it 
included a limited number of patients in each histology. 
Second, clinical annotation was not available since 
the database was de-identified. Third, the definition of 
“actionable” and the level of evidence needed for such 
a determination is a matter of debate and in constant 
evolution [34]. Fourth, the use of tissue-based next 
generation sequencing as a comparison to establish clinical 
utility was not accessible for this group of de-identified 
patients. However, because many of our patients were 
on treatment, it is important to note that concordance to 
tissue-based NGS is challenged by the fact that ctDNA 
is a dynamic measure and the original oncogenic driver 
mutations may become undetectable in the plasma of 
patients that are responding, or conversely, new resistance 
mutations may arise in ctDNA that were not seen in the 
original tissue biopsy [35–37]. Further, ctDNA tests may 
measure shed DNA from multiple metastases. On the other 
hand, ctDNA tests may not be sensitive enough to detect 
some tissue NGS alterations. Additional studies will need 
to perform in-depth analyses of the concordance between 
tissue and ctDNA molecular results to better understand 
the observations from each test. Finally, whether or not 
the patients would have responded to these drugs could 
not be addressed in this study, and will require further 
investigation.
In conclusion, “liquid biopsies” are non-
invasive, and have several advantages compared to 
tissue biopsies. Most importantly, they require only 
Table 2: Alterations and actionability in 171 patients with diverse cancer types
Patients cases 
 
 
 
Histology
No reportable 
alteration (N, %)
Patients had 
alteration(s), 
but none 
actionable  
(N, %)
Approved 
drug(s) in 
the disease 
available  
(N, %)b
(On-label)
Approved 
drug(s) in 
another disease 
available  
(N, %)b
(Off-label)
Experimental 
treatmentb 
(Clinical trials) 
available  
(N, %)
Lung (N=40) 8 (20%) 8 (20%) 5 (12.5%) 24 (60%) 24 (60%)
Breast (N=40) 12 (30%) 7 (17.5%) 2 (5%) 21 (52.5%) 21 (52.5%)
Glioblastoma (N=33) 24 (73%) 3 (9%) 0 6 (18%) 6 (18%)
Genitourinary (N=10) 2 (20%) 4 (40%) 1 (10%) 4 (40%) 4 (40%)
Gastrointestinal (N=6) 0 1 (17%) 1 (17%) 5 (83%) 5 (83%)
Othera (N=42) 26 (62%) 7 (16.7%) 0 8 (19%) 9 (21%)
OVERALL (N=171) 72 (42%) 30 (17.5%) 9 (5%) 68 (39.8%) 69 (40%)
aOther included: unknown primary, n=39; melanoma, n=1; sarcoma, n=1; thymic sarcoma, n=1.
bNote: there is some overlapping as some patients had approved agents on and off-label, as well as experimental drugs 
options for their disease. In total, 68 patients (39.8%) had one or more approved drug(s) as an option: 9 patients had both 
on- and off-label options, 59 had off-label only.
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a small amount of blood, rather than a biopsy that 
can be invasive, painful, and, in some cases, have 
complications. Evaluation of ctDNA obtained from 
liquid biopsies is therefore also amenable to repeat 
sampling. Furthermore, obtaining a blood sample is 
efficient and inexpensive compared to obtaining a tissue 
biopsy. Indeed, biopsies often cost thousands of dollars; 
transthoracic and transbronchial lung needle biopsies 
have been reported to cost over $14,000 on average, 
based on a population-based national Medicare sample 
[38]. Finally, it is now known that there is molecular 
heterogeneity within and between tumors in the same 
patient [14]. Therefore, theoretically, ctDNA results 
may reflect genomic aberrations in DNA shed from 
multiple metastatic sites. Our observations suggest 
that, in our population, 40% of patients (69/171) 
carried potentially actionable aberrations; almost all 
of them had an aberration that could be targeted by an 
approved drug (n = 68/69). However, only a minority 
of individuals (9 patients) had aberrations that could 
be targeted by drugs approved for their type of cancer 
(on-label). This biopsy-free test has intrinsic clinical 
utility by obviating the need for repeat invasive-
tissue biopsies at the time of progression of a visceral 
malignancy. In cases where the ctDNA-based NGS 
panel detects no genomic alterations, an invasive 
tissue biopsy could then be considered to evaluate the 
genomic status of the tumor. The rate of actionability 
for the NGS test described here may further increase 
with more comprehensive panels. To extend evidence 
of clinical utility, the value of ctDNA-based, multi-
panel gene assays, such as those used in this study, 
in monitoring patients and predicting tumor response 
merits investigation in prospective trials.
MATERIALS AND METHODS
Patients
We retrospectively reviewed the liquid biopsy results 
of 171 consecutive de-identified patients with diverse 
cancers who were seen at UC San Diego Moores Cancer 
Center. Blood samples were collected between June, 2014 
and January 2015. Analysis was performed per UCSD IRB 
exempt approval for study of pre-existing de-identified 
data. Analysis of usage patterns of liquid biopsies at our 
institution indicates that about 95% of patients who have 
had these tests performed have advanced or metastatic 
disease. In addition, two series of healthy volunteers were 
tested as controls (N = 79 followed by N = 143) (source: 
AllCells, http://www.allcells.com).
Next generation sequencing
Next generation digital sequencing was performed 
by Guardant Health (Guardant360, www.guardanthealth.
com/guardant360/), a Clinical Laboratory Improvement 
Amendments (CLIA)-certified and College of American 
Pathologists (CAP)-accredited clinical laboratory 
(Guardant Health, Inc.). At the time of this study, this 
test identifies potential tumor-related genomic alterations 
via complete exon sequencing of 54 cancer-related genes 
including amplifications in ERBB2, EGFR, and MET 
through analysis of cell-free DNA extracted from plasma 
(extracted from two blood tubes), Supplementary Table 
S1. This circulating tumor DNA assay has high analytic 
sensitivity (detects single molecules of somatic tumor 
DNA in 10 mL blood samples), high clinical sensitivity 
(detects 85%+ of the single nucleotide variants detected 
in tissue in advanced cancer patients) (for stage III and 
IV solid cancers) and analytic specificity (>99.9999%) 
(Sensitivity was determined by comparing 165 sequential 
matched plasma and tissue samples (Guardant Health, 
data on file). Specificity >99.9999% represents the 
analytic specificity, calculated from a controlled study of 
20 samples comparing to exome sequencing of basepair 
calls for all 78,000 base pairs in the panel (genomic 
DNA analyzed by an independent CLIA-licensed and 
CAP-accredited clinical laboratory). A high degree of 
specificity is critical to eliminate the false positives (noise) 
that otherwise accompany sequencing DNA at very low 
concentrations over long targeted regions (in this case 
~78,000 base pairs per sample). All cell-free DNA is 
sequenced, including the germline cell-free DNA that 
is derived from leukocyte lysis and the somatic ctDNA. 
Single nucleotide variants are quantitated as mutant allele 
fraction (MAF) which is the number of ctDNA fragments 
divided by the number of wild type DNA fragments that 
overlap the same mutated nucleotide base position. Gene 
amplifications are reported as absolute gene copy number 
in plasma. In each sequencing run, a normal control 
sample is included (Guardant360 digital sequencing panel, 
Guardant Health Inc, data on file).
Definition of actionability
Actionability implies that the protein product of 
a genomic abnormality can be impacted by a specific 
targeted drug. An actionable alteration was defined 
as an alteration that was either the direct target (such 
as an EGFR inhibitor targeting an EGFR mutation), 
or a pathway component (such as an mTOR inhibitor 
for a PIK3CA mutation (since mTor is downstream of 
PIK3CA)) that could be targeted by at least one approved 
(by the Food and Drug Administration) or investigational 
drug in a clinical trial. (Actionability determination was 
based on the ability of drugs that are small molecule 
inhibitors to impact the aberration, with low IC50 against 
the product of the aberration or effectors not more than 
four signals removed from the gene aberration or its 
product; if an altered gene product could be targeted by 
an antibody whose primary target was the altered gene 
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product, it was also considered actionable). Actionability 
was crosschecked by two investigators, including the 
senior investigator (RK) [34].
Data extraction and analysis
Demographic information such as gender, age, 
primary tumor site, as well as the dates of sample reception, 
dates of results, list of alterations and actionability data 
(included: number of actionable alterations, and more 
specifically, the number of alterations with an approved 
drug available in the disease (on-label use), the number of 
alterations with an approved drug in another disease (off-
label use), and the number of alterations with experimental 
drug(s) available (clinical trials)) were extracted from the 
reports and analyzed.
Most of the statistical analysis was descriptive in 
nature. When appropriate, median and 95% confidence 
intervals (95% CI) or range were reported. The sample 
size was determined by the available patients with genetic 
testing information. Analysis performed by author MS 
using SPSS version 22.0.
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